Daniel Solomon, MD, MPH, has practiced rheumatology for more than 20 years, all while conducting translational and clinical research and teaching young clinicians. Soon, he will also step into the role of editor in chief of Arthritis & Rheumatology, as Richard J. Bucala, MD, PhD, ends his tenure. He will assume some duties during a…
The patient medical history is far more prominent in clinical decisions for rheumatology than for many common chronic diseases in which a gold standard biomarker, such as blood pressure or serum glucose, is applicable to diagnosis and management of all individual patients.1 Components of a subjective patient history may be recorded as structured, quantitative, standard,…
The recommendations include updated disease activity measures and a new set of functional status assessment measures for rheumatoid arthritis.
ATLANTA—The authors of the new draft ACR treatment guideline for the management of gout presented the draft guideline on Nov. 13 at the 2019 ACR/ARP Annual Meeting. Based on evidence from more than 130 published studies, there are 42 recommendations, of which 16 were strong, including 27 for urate-lowering therapy (ULT) management, 13 of which…
Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.
As the 21st century unfolds, rheumatologists will most likely transition from prescribing lupus patients broad immunosuppressants to more targeted treatment approaches. But to make this happen and advance research, the challenges experienced in lupus clinical trial design must be addressed…
A 2019 update of the ACR’s previous clinical practice guideline on axial spondyloarthritis is now available online. Lead investigator Michael Ward, MD, shares advice for implementing the guideline updates, including those related to sequencing and tapering biologics, and knowing when to obtain images.
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…
When Reshma Khan, MD, a rheumatologist at the Family Arthritis Center, Jupiter, Fla., relocated from Michigan three-and-a-half years ago, she missed the camaraderie and friendships she’d made in Michigan. “I’m a very social person, and after finishing my research, residency and fellowship in Michigan, I missed those close friendships [when I moved to Florida],” Dr….
In a study of bDMARD-naive patients with active PsA and skin disease, ixekizumab proved more efficacious than adalimumab…